Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Binimetinib in Advanced KRAS Mutant NSCLC
NCT03170206Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib and binimetinib in non-small cell lung cancer (NSCLC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 2 years, Safety and tolerability of Palbocilib and Binimetinib at 2 years and 1 more. Started May 2017; status: completed.
02
Drugs
palbociclibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03170206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170206.